A Follow-on Biologics Regime Without Strong Data Exclusivity Will Stifle the Development of New Medicines

  • Recommend
  • Tweet
  • Print
  • Email

BIO recognizes the importance of providing the fruits of science and innovation in healthcare for the benefit of all American citizens. BIO represents both small and large biotechnology companies: some with products already on the market and most with their lead product still at the development stage with many years ahead of them before they can expect market approval.

Download the full PDF

Hide Date: 
Show